HCPCS Code J7325: Hyaluronan or Derivative, Synvisc or Synvisc-One, for Intra-Articular Injection, 1 mg

## **Documentation requirements** Your documentation should include: - **Clinical diagnosis**: Clearly document the patient's diagnosis, such as knee osteoarthritis, unilateral secondary osteoarthritis, or bilateral secondary osteoarthritis. This information is crucial for justifying the use of hyaluronan or derivative injections. - **Failure of conservative therapies**: Provide evidence that the patient has not adequately responded to conservative nonpharmacologic therapy and other conservative therapies, including physical therapy, simple analgesics, and corticosteroid injections. - **Functional limitation**s: Record the patient's functional capacity and how the condition impacts daily activities, supporting the need for intra-articular injections to alleviate symptoms. - **Injection details**: Document specifics of the intra-articular injection, including the dose, site of administration, and any adverse reactions or complications observed during or after the procedure. - **Treatment plan**: Outline the proposed treatment plan, including the number of injections, frequency, and any follow-up care or assessments planned to evaluate the effectiveness of the treatment. - **Medical necessity statement**: Include a statement from the healthcare provider that explicitly states the medical necessity of the intra-articular injection 1 mg of Synvisc or Synvisc-One for the patient's condition. By ensuring that these documentation requirements are met, providers can facilitate the approval process and ensure appropriate reimbursement for the services rendered. Always refer to the specific Medicare Administrative Contractor (MAC) guidelines, as coverage policies may vary.

## **Billing requirements** When billing for HCPCS code J7325, providers should follow these key guidelines to ensure proper reimbursement: - **Drug code and J code**: J7325 is the specific J code assigned for Synvisc or Synvisc-One, reflecting 1 mg of hyaluronan or derivative administered via intra-articular injection. Use this code only for the indicated drug administered. - **Medical necessity**: The injection must be considered medically necessary, typically after failure of conventional therapies such as physical therapy, analgesics, or corticosteroid injections. - **Dosing and frequency**: Document the last injection and ensure that the timing of the current injection aligns with coverage guidelines for osteoarthritis of the knee. Typically, single intra-articular injections are billed individually per administration. - **Reimbursement**: Payment is generally based on the average sales price (ASP) of the drug, adjusted per Medicare guidelines. Ensure claims accurately reflect the drug code and dosage administered. - **Claims submission**: Include all relevant documentation in the claim to justify the medical necessity and confirm the patient meets coverage criteria for osteoarthritis of the knee. Following these billing requirements helps prevent denials and ensures compliance with Medicare and commercial payer policies.

## **Other relevant codes** Comparable hyaluronan injection codes include: - **J7321** – Hyalgan, Supartz, or Visco-3 (per dose) - **J7323** – Euflexxa (per dose) - **J7324** – Orthovisc (per dose) - **J7326** – Gel-one (single injection)